Thorsten P. Degenhardt
Operationeel Directeur bij Mycovia Pharmaceuticals, Inc.
Profiel
Thorsten P.
Degenhardt is currently the Chief Operating Officer at Mycovia Pharmaceuticals, Inc. He previously worked as a Project Director at BioStratum, Inc. and as a Vice President-Drug Development at Cempra Pharmaceuticals, Inc. Prior to his industry experience, he was an Assistant Professor at the University of South Carolina.
Degenhardt holds a graduate degree from Technische Universität Darmstadt and a doctorate from Ruprecht-Karls-Universität Heidelberg.
Actieve functies van Thorsten P. Degenhardt
| Bedrijven | Functie | Begin |
|---|---|---|
Mycovia Pharmaceuticals, Inc.
 Mycovia Pharmaceuticals, Inc. BiotechnologyHealth Technology Mycovia Pharmaceuticals, Inc. develops novel drugs in areas of unmet medical need, with an initial focus in women?s health. Its product candidate, VT-1161, engages in developed as a treatment for recurrent vulvovaginal candidiasis. The company was founded in 2018 and is headquartered in Durham, NC. | Operationeel Directeur | - |
Eerdere bekende functies van Thorsten P. Degenhardt
| Bedrijven | Functie | Einde |
|---|---|---|
BioStratum, Inc.
 BioStratum, Inc. Pharmaceuticals: MajorHealth Technology BioStratum, Inc. develops and distributes pharmaceutical products. Its products are used for treatment of diabetes and diabetic complications. The firm also develops anti-tumor, cancer, diabetic kidney disease and diabetic eye disease drugs. The company was founded by Karl Tryggvason and J. Wesley Fox in 1994 and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
| University of South Carolina | Corporate Officer/Principal | - |
Cempra Pharmaceuticals, Inc.
 Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | - |
Opleiding van Thorsten P. Degenhardt
| Technische Universität Darmstadt | Graduate Degree |
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Cempra Pharmaceuticals, Inc.
Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Health Technology |
BioStratum, Inc.
BioStratum, Inc. Pharmaceuticals: MajorHealth Technology BioStratum, Inc. develops and distributes pharmaceutical products. Its products are used for treatment of diabetes and diabetic complications. The firm also develops anti-tumor, cancer, diabetic kidney disease and diabetic eye disease drugs. The company was founded by Karl Tryggvason and J. Wesley Fox in 1994 and is headquartered in Durham, NC. | Health Technology |
Mycovia Pharmaceuticals, Inc.
Mycovia Pharmaceuticals, Inc. BiotechnologyHealth Technology Mycovia Pharmaceuticals, Inc. develops novel drugs in areas of unmet medical need, with an initial focus in women?s health. Its product candidate, VT-1161, engages in developed as a treatment for recurrent vulvovaginal candidiasis. The company was founded in 2018 and is headquartered in Durham, NC. | Health Technology |
